The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation
Open accessAbstract
Atrial fibrillation (AF) is the most common arrhythmia in clinical practise and its prevalence is increasing. Over the last 25 years, flecainide has been used extensively worldwide, and its capacity to reduce AF symptoms and provide long-term restoration of sinus rhythm (SR) has been well documented. The increased mortality seen in patients treated with flecainide in the Cardiac Arrhythmia Suppression Trial (CAST) study, published in 1991, still deters many clinicians from using flecainide, denying many new AF patients a valuable treatment option. There is now a body of evidence that clearly demonstrates that flecainide has a favourable safety profile in AF patients without significant left ventricular disease or coronary heart disease. As a result of this evidence, flecainide is now recommended as one of the first-line treatment options for restoring and maintaining SR in patients with AF under current treatment guidelines. The objective of this article is to review the literature pertaining to the pharmacological characteristics, safety and efficacy of flecainide, and to place this drug in the context of current therapeutic management strategies for AF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A comparison of rate control and rhythm control in patients with atrial fibrillation
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa021328 · Cited by 4,405
Rhythm control versus rate control for atrial fibrillation and heart failure
Roy, D., Talajic, M., Nattel, S., Wyse, D. G., Dorian, P., Lee, K. L., Bourassa, M. G., Arnold, J. M. O., Buxton, A. E., Camm, A. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708789 · Cited by 1,585
Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study.
Sanfilippo, A. J., Abascal, V. M., Sheehan, M., Oertel, L. B., Harrigan, P., Hughes, R. A., & Weyman, A. E. (1990) · Circulation · doi:10.1161/01.cir.82.3.792 · Cited by 739
Outpatient treatment of recent-onset atrial fibrillation with the “Pill-in-the-Pocket” approach
Alboni, P., Botto, G. L., Baldi, N., Luzi, M., Russo, V., Gianfranchi, L., Marchi, P., Calzolari, M., Solano, A., Baroffio, R., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041233 · Cited by 479 · cited 2×
“This, so-called, ‘pill-in-the-pocket’ approach has become a means of treating patients with paroxysmal or persistent symptomatic AF with an average ventricular rate of 70/min or greater.(29) However, this”
BackgroundSecular trends in the prevalence of atrial fibrillation: The Framingham study
Wolf, P. A., Benhamin, E. J., Belanger, A. J., Kannel, W. B., Levy, D., & D'Agostino, R. B. (1996) · American Heart Journal · doi:10.1016/s0002-8703(96)90288-4 · Cited by 446 · cited 1×
“quently rapid ventricular rate—is on the increase, to an extent that cannot be fully accounted for by factors such as an ageing population or an increasing prevalence of cardiovascular disease.(1,2)”
BackgroundRate vs Rhythm Control in Patients With Atrial Fibrillation: A Meta-analysis
de Denus, S. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.258 · Cited by 239
Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment
Crijns, H. J., van Gelder, I. C., & Lie, K. I. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90282-2 · Cited by 120
Self-citationShort- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias
Hohnloser, S. H., & Zabel, M. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91071-b · Cited by 74
Cited by
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
Andrade, J. G., Aguilar, M., Atzema, C., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 562
Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide
Tamargo, J., Le Heuzey, J.-Y., & Mabo, P. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1832-0 · Cited by 276
Self-citation
Metadata
- Authors
- Aliot, E., Capucci, A., Crijns, H. J., Goette, A., & Tamargo, J.
- Venue
- Europace
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-12-07
- Volume
- 13
- Issue
- 2
- Pages
- 161-173
- ISSN
- 1099-5129 (ISSN-L)
- 1532-2092
- OpenAlex
- W2170907276
- Cited by
- 167
- References
- 8
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. https://app.cochat.ai/papers/10.1093/europace/euq382
- The paper
- Aliot, E., Capucci, A., Crijns, H. J., Goette, A., & Tamargo, J. (2011). Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. https://doi.org/10.1093/europace/euq382
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.